Lovastatin Tablet
Product Images NDC 71610-775

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 71610-775). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 40 mg (71610 0775 30)

Lovastatin USP 40 mg oral tablets label. The label states the product name, strength, quantity of 30 tablets, storage instructions between 20-25 degrees Celsius, and manufacturer information as Carlsbad Technology Inc., with packaging by Aphena Pharma, Cookeville, TN. It includes an NDC number 71610-0775-30 and lot and expiration data fields.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure of Lovastatin showing its molecular framework with hydroxyl, methyl, and lactone groups.*

FDA Label Image

Table I (Lov00 0004 02)

A data table titled 'The Effect of Other Drugs on Lovastatin Exposure When Both Were Co-administered.' It lists drugs co-administered with lovastatin, number of subjects, dosing details for coadministered drugs and lovastatin, and AUC ratios comparing lovastatin exposure with and without the coadministered drug or grapefruit juice. Drugs include Gemfibrozil, Itraconazole, Grapefruit Juice, Cyclosporine, and Diltiazem with various dose regimens and their impact on lovastatin pharmacokinetics.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' displays the proportion of participants without events over 6 years of follow-up. Two lines compare Lovastatin and placebo groups, showing a 37% risk reduction favoring Lovastatin with statistical significance (p < 0.001). The y-axis represents the proportion without event, and the x-axis denotes years of follow-up.*

FDA Label Image

Table Vii (Lov00 0005 04)

A data table titled 'Table VII Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis.' It lists interacting agents such as strong CYP3A4 inhibitors, HIV protease inhibitors, gemfibrozil, cyclosporine, danazol, diltiazem, dronedarone, verapamil, amiodarone, and grapefruit juice along with prescribing recommendations for lovastatin use, including contraindications, dosage limits, and avoidance advice.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.